PRA Health Sciences
4141 ParkLake Avenue, Suite 530
244 articles with PRA Health Sciences
ICON plc announced in connection with the proposed acquisition by ICON of PRA Health Sciences, Inc. pursuant to which Indigo Merger Sub, Inc., a wholly owned subsidiary of ICON will merge with and into PRA, with PRA surviving the Merger, the pricing on June 16, 2021 of $500 million aggregate principal amount of Merger Sub’s 2.875% Senior Secured Notes due 2026 in a private offering.
PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma
Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act.
Net new business of $797.2 million; representing growth of 31.8%; Net book-to-bill of 1.24 excluding reimbursement revenue
PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics
PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and therapeutic pharmacovigilance requirements
PRA Health Sciences selected by Maryland State Medical Society to supply remote patient monitoring and telehealth servicesMaryland-based physicians can quickly deploy remote care options for patients with PRA’s digital health technology
PRA Health Sciences and the Maryland State Medical Society announced that Care Innovations, a PRA Health Sciences company, was selected by MedChi to be a preferred provider of remote patient monitoring, telehealth, and digital health services for its network of 22,000+ licensed physicians who practice across 50+ medical specialties.
PRA’s remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human growth hormone treatment system
PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, selected PRA’s remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment system.
PRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical Programs
Four-part, patient-focused toolkit is available for download at no cost and allows sponsors to identify risks to the efficiency and success of their trials
ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research
The consolidation brings together two organizations with a history of robust growth and performance ready to build on this strength using the outstanding talent of both companies to deliver enhanced value to patients, customers, employees and shareholders.
Net new business of $872.4 million in the fourth quarter excluding reimbursement revenue; representing growth of 32.4%; Net book-to-bill of 1.42
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 2021
PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilities
PRA’s remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionality
PRA Health Sciences appoints senior FDA official to lead new Global Center of Excellence for Decentralized Clinical Trial Strategy
Dr. Isaac Rodriguez-Chavez brings vast expertise in regulatory compliance and clinical research methodology to PRA’s industry-leading DCT practice
$796.3 million of total revenue; representing growth of 2.0% at actual foreign exchange rates and 1.3% on a constant currency basis
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today it has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to be a member of its updated Clinical Studies Network (CSN).
PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials
The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials
PRA Health Sciences, Inc. announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effective September 14, 2020.
PRA Health Sciences, Inc. Reports Second Quarter 2020 Results and Provides Third Quarter and Full Year 2020 Guidance
PRA Health Sciences, Inc. reported financial results for the quarter ended June 30, 2020.
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2020 results after the market closes on Thursday, August 6, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service.